Will it matter
This week both Lilly and Novo Nordisk report earnings and while they are still in the insulin business insulin is no longer their bread-and-butter product. Yes, they still sell a ton of insulin but when it comes to making money GLP-1’s is what drives profits. The fact is these two legacy diabetes companies are now GLP-1 first and insulin second. Insulin for all practical purposes has become a commodity.
Now in a normal commodity market prices decline however the wacky world of diabetes is not normal. The fact is insulin may be a commodity, but . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.